Determination of asymmetric dimethylarginine in biological fluids: A paradigm for a successful analytical story

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 5, 2008, Pages 592-600

  Tsikas, Dimitrios ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Comparison; Liquid chromatography; Mass spectrometry; Quantification; Validation

Indexed keywords

DIMETHYLARGININASE; NITRIC OXIDE; ARGININE; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; UNCLASSIFIED DRUG;

ACCURACY; BODY FLUID; CALIBRATION; CLINICAL EVALUATION; CLINICAL RESEARCH; CONCENTRATION RESPONSE; DERIVATIZATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS FRAGMENTOGRAPHY; REFERENCE VALUE; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARD; TANDEM MASS SPECTROMETRY; BLOOD; MASS SPECTROMETRY; SOLID PHASE EXTRACTION; URINE;

ARGININE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MASS SPECTROMETRY; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION;

EID: 55749112881     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3283065bb1     Document Type: Review

References (56)

1. Tsikas D, Böger RH, Sandmann J, et al. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 2000; 478:1-3.
2. Kelm M,Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res 1990; 66:1561-1575.
3. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006; 147 (Suppl. 1):S193-S201.
4. Cooke JP. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of angiogenesis. Eur J Clin Pharmacol 2006; 62:115-121.
5. Förstermann U. Endothelial NO synthase as a source of NO and superoxide. Eur J Clin Pharmacol 2006; 62:5-12.
6. Kielstein A, Tsikas D, Galloway GP, Mendelson JE. Asymmetric dimethylarginine (ADMA)- A modulator of nociception in opiate tolerance and addiction? Nitric Oxide 2007; 17:55-59.
7. Leiper JM, Vallance P. The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol 2006; 62:33-38.
8. G-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989; 264:10205-10209.
9. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23:1455-1459.
10. Kielstein JT, Tsikas D, Fliser D. Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 2006; 62:39-44.
11. Lenzen H, Tsikas D, Boger RH. Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study. Eur J Clin Pharmacol 2006; 62:45-49.
12. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007; 13:198-203.
13. Bode-Boger SM. Effect of L-arginine supplementation on NO production in man. Eur J Clin Pharmacol 2006; 62:91-99.
14. Tsikas D. Analysis of the L-arginine/nitric oxide pathway: the unique role of mass spectrometry. Curr Pharmaceut Anal 2005; 1:15-30.
15. Tsikas D, Gutzki FM, Stichtenoth DO. Circulating and excretory nitrite and nitrate as indicators of nitric oxide synthesis in humans: methods of analysis. Eur J Clin Pharmacol 2006; 62:51-59.
16. Boudko D. Bioanalytical profile of the L-arginine/nitric oxide pathway and its evaluation by capillary electrophoresis. J Chromatogr B2007; 851:186-210.
17. Thum T, Bauersachs J. Microarray-based gene expression profiling to elucidate cellular response to nitric oxide- a review from an analytical and biomedical point of view. J Chromatogr B 2007; 851:3-11.
18. Giustarini D, Milzani A, Dalle-Donne I, Rossi R. Detection of S-nitrosothiols in biological fluids: a comparison among the most widely applied methodologies. J Chromatogr B 2007; 851:1 24-139.
19. Ryberg H, Caidahl K. Chromatographic and mass spectrometric methods for quantitative determination of 3-nitrotyrosine in biological samples and their application to human samples. J Chromatogr B 2007; 851:160-171.
20. TeerlinkT. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. J Chromatogr B 2007; 851:21-29.
21. Horowitz JD, HeresztynT. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B 2007; 851:42-50.
22. Tsikas D. A critical review and discussion of analytical methods in the L-arginine/nitric oxide (NO) area of basic and clinical research. Anal Biochem 2008; (in press). doi: 10.1016/j.ab.2008.04.01 8.
23. Lücke T, Kanzelmeyer N, Kemper MJ, et al. Developmental changes in the L-arginine/nitric oxide pathway from infancy to adulthood: plasma asymmetric dimethylarginine levels decrease with age. Clin Chem Lab Med 2007; 45: 1525-1530.
24. Tsikas D, Thum T, Becker T, et al. Accurate quantification of dimethylamine (DMA) in human urine by gas chromatography-mass spectrometry as pentafluorobenzamide derivative: evaluation of the relationship between DMA and its precursor asymmetric dimethylarginine (ADMA) in health and disease. J Chromatogr B 2007; 851:229-239.
25. Martens-Lobenhoffer J, Bode-Boger SM. Chromatographic-mass spectrometric methods for the quantification of L-arginine and its methylated metabolites in biological fluids. J Chromatogr B 2007; 851:30-41.
26. Caussé E, Siri N, Arnal JF, et al. Determination of asymmetrical dimethylarginine by capillary-electrophoresis-laser-induced fluorescence. J Chromatogr B 2000; 741:77-83.
27. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004; 42:1377-1383.
28. Schwedhelm E, Maas R, Tan-Andreesen J, et al. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated derivatives in human and mouse plasma. J Chromatogr B 2007; 851:211-219.
29. Schwedhelm E, Benndorf RA, Boger RH, Tsikas D. Mass spectrometric analysis of F2-isoprostanes: markers and mediators in human diseases. Curr Pharmaceut Anal 2007; 3:39-51.
30. Vishwanathan K, Tackett RL, Stewart JT, Bartlett MG. Determination of arginine and methylated arginines in human plasma by liquid chromatography- tandem mass spectrometry. J Chromatogr B 2000; 748:157-166.
31. TeerlinkT, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002; 303:131-137.
32. Tsikas D, Schubert B, Gutzki FM, et al. Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl estertri (N- pentafluoropropionyl) derivative. J Chromatogr B 2003; 798:87-99.
33. G′-dimethyl-L- arginine in plasma by liquid chromatography as AccQ-Fluor fluorescent derivatives. J Chromatogr B 2004; 805:325-329.
34. Martens-Lobenhoffer J, Krug O, Bode-Böger SM. Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique. J Mass Spectrom 2004; 39:1287-1294.
35. Schwedhelm E, Tan-Andreesen J, Maas R, et al. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005; 51:1268-1271.
36. Kirchherr H, Kühn-Velten WN. HPLC-tandem mass spectrometric method for rapid quantification of dimethylarginines in human plasma. Clin Chem 2005; 51:249-252.
37. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 2005; 43:1130-1138.
38. TeerlinkT. Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological samples by HPLC. Methods Mol Med 2005; 108:263-274.
39. de Jong S, Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 2006; 353:287-289.
40. G-dimethyl-L-arginine in rat plasma and dimethylarginine dimethylaminohydrolase activity in rat kidney using a monolithic silica column. J Chromatogr B 2006; 843:1 70-174.
41. G-dimethyl-L-arginine, an endogenous NO synthase inhibitor, by gas chromatography-mass spectrometry. J Chromatogr B 2004; 809:59-65.
42. Martens-Lobenhoffer J, Bode-Boger SM. Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. J Chromatogr B 2003; 798:231-239.
43. Schulze F, Maas R, Freese R, et al. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005; 35:622-626.
44. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 2005; 10 (Suppl 1):S89-S95.
45. Martens-Lobenhoffer J, Westphal S, Awiszus F, et al. Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA? Clin Chem 2005; 51:2188-2189.
46. Široká R, Trefil K, Rajdl D, et al. Asymmetric dimethylarginine- comparison of HPLC and ELISA methods. J Chromatogr B 2007; 850:586-587.
47. Valtonen P, Karppi J, Nyyssönen K, et al. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B 2005; 828:97-102.
48. Krempl TK, Maas R, Sydow K, et al. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005; 26:1841-1851.
49. Dooley A, Gao B, Bradley N, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology 2006; 45:676-684.
50. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310.
51. Lu TM, Ding YA, Leu HB, et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004; 94:157-161.
52. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005; 46:1693-1701.
53. ThumT, Fleissner F, KlinkI, et al. Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I. J Clin Endocrinol Metab 2007; 92:4172-4179.
54. Leifke E, Kinzel M, Tsikas D, et al. Effects of normalization of plasma testosterone levels in hypogonadal men on plasma levels and urinary excretion of asymmetric dimethylarginine (ADMA). Horm Metab Res 2008; 40: 56-59.
55. Beckmann B, Gutzki FM, Tsikas D. Sensitivity enhancement of a GC-MS/MS method for circulating asymmetric dimethylarginine (ADMA) by plasma ultrafiltrate reduction. Anal Biochem 2008; 372:264-266.
56. Maas R, Tan-Andreesen J, Schwedhelm E, et al. A stable-isotope based technique for the determination of dimethylarginine dimethylaminohydrolase (DDAH) activity in mouse tissue. J Chromatogr B 2007; 851:220-228.